JP4704435B2 - ニューロン再生 - Google Patents

ニューロン再生 Download PDF

Info

Publication number
JP4704435B2
JP4704435B2 JP2007537361A JP2007537361A JP4704435B2 JP 4704435 B2 JP4704435 B2 JP 4704435B2 JP 2007537361 A JP2007537361 A JP 2007537361A JP 2007537361 A JP2007537361 A JP 2007537361A JP 4704435 B2 JP4704435 B2 JP 4704435B2
Authority
JP
Japan
Prior art keywords
gene silencing
molecule
seq
ntr
sina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007537361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008516628A5 (enExample
JP2008516628A (ja
Inventor
アフメド，ズベアー
ベリー，マーティン
ローガン，アン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuregenix Ltd
Original Assignee
Neuregenix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuregenix Ltd filed Critical Neuregenix Ltd
Publication of JP2008516628A publication Critical patent/JP2008516628A/ja
Publication of JP2008516628A5 publication Critical patent/JP2008516628A5/ja
Application granted granted Critical
Publication of JP4704435B2 publication Critical patent/JP4704435B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2007537361A 2004-10-22 2004-10-22 ニューロン再生 Expired - Fee Related JP4704435B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2004/004504 WO2006043014A1 (en) 2004-10-22 2004-10-22 Neuron regeneration

Publications (3)

Publication Number Publication Date
JP2008516628A JP2008516628A (ja) 2008-05-22
JP2008516628A5 JP2008516628A5 (enExample) 2008-09-04
JP4704435B2 true JP4704435B2 (ja) 2011-06-15

Family

ID=34958935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007537361A Expired - Fee Related JP4704435B2 (ja) 2004-10-22 2004-10-22 ニューロン再生

Country Status (7)

Country Link
US (1) US7943755B2 (enExample)
EP (1) EP1802755A1 (enExample)
JP (1) JP4704435B2 (enExample)
CN (1) CN101084309A (enExample)
AU (1) AU2004324236B2 (enExample)
CA (1) CA2584921A1 (enExample)
WO (1) WO2006043014A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014077A2 (en) * 2005-07-21 2007-02-01 Alnylam Pharmaceuticals, Inc. Rnai modulation of the rho-a gene and uses thereof
TW201034684A (en) * 2009-02-18 2010-10-01 Genentech Inc Method for inhibiting neurodegeneration
CN102666856B (zh) 2009-11-08 2016-04-06 夸克制药公司 定向至RhoA靶基因的双链RNA化合物在制造治疗神经性疼痛的药物中的用途
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410323B1 (en) * 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
CA2398282A1 (en) * 2000-02-11 2001-08-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
AU2002210791A1 (en) * 2000-07-28 2002-02-13 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
JP2007528202A (ja) * 2003-03-28 2007-10-11 株式会社インテレクチャル・プロパティ・コンサルティング 神経再生のための組成物および方法
EP1675949A2 (en) * 2003-10-23 2006-07-05 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)

Also Published As

Publication number Publication date
US20080253989A1 (en) 2008-10-16
CN101084309A (zh) 2007-12-05
AU2004324236A1 (en) 2006-04-27
CA2584921A1 (en) 2006-04-27
EP1802755A1 (en) 2007-07-04
AU2004324236B2 (en) 2010-12-09
US7943755B2 (en) 2011-05-17
WO2006043014A1 (en) 2006-04-27
JP2008516628A (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
US9198981B2 (en) Modulation of angiogenesis
US8410067B2 (en) Inhibition of versican with siRNA and other molecules
JP2016127853A (ja) Ｈｓｐ４７発現の調節
US12031135B2 (en) p63 inactivation for the treatment of heart failure
Zhou et al. Targeting RPTPσ with lentiviral shRNA promotes neurites outgrowth of cortical neurons and improves functional recovery in a rat spinal cord contusion model
US10036016B2 (en) Methods for inducing glucose uptake
US9518098B2 (en) Uses of NANOG inhibitors and related methods
Wu et al. Actions of neuropoietic cytokines and cyclic AMP in regenerative conditioning of rat primary sensory neurons
JP2008516628A (ja) ニューロン再生
JP2023532536A (ja) ｍｉＲＮＡ－４８５ハンチントン病の阻害剤
JP2023513188A (ja) 遺伝子の発現増加のためのｍｉｒｎａ－４８５阻害剤
KR101292924B1 (ko) ＧＣＨ1을 표적으로 하는 ｓｉＲＮＡ를 포함하는 재조합 벡터 및 이를 함유하는 신경병증성 통증 완화용 약제학적 조성물
WO2017028782A1 (zh) 脑源性神经营养因子前体蛋白用作治疗情感障碍的靶点
CN111727246A (zh) Ror2抑制剂及其在治疗和/或预防软骨缺失中的用途
US20050250123A1 (en) Reducing galectin-12 activity to reduce formation of adipocytes
CN101818150B (zh) 神经元再生
KR100937230B1 (ko) Ｎｏｘ4 유전자와 상보결합할 수 있는 ｓｉＲＮＡ를 유효성분으로 포함하는 염증치료제
US9567583B2 (en) Method for treating glioma using Tarbp2 expression inhibitor
KR20080044909A (ko) 세포 내로 리보핵산의 전달을 위한 약학 조성물
KR101088764B1 (ko) Ｎｋ１ｒ 단백질 억제제를 포함하는 알코올 의존 예방 및 치료용 조성물
KR101252891B1 (ko) ＧＣＨ1을 표적으로 하는 ｓｉＲＮＡ를 포함하는 재조합 벡터 및 이를 함유하는 신경병증성 통증 완화용 약제학적 조성물
WO2024197320A2 (en) Targeting sf3b2 for axonal protection in central nervous system neurodegenerative diseases
WO2007138236A1 (en) Sheddase enzymes for neuron growth
KR20220155585A (ko) Sirt1 발현을 사용하는 진단 방법
Ambati et al. Modulation of Angiogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110119

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110309

LAPS Cancellation because of no payment of annual fees